Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Wednesday 16 June, 2021

Omega Diagnostics Gp

Notice of Results

RNS Number : 0108C
Omega Diagnostics Group PLC
16 June 2021


("Omega" or the "Company" or the "Group")


Notice of results

Investor presentation


Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, will issue its financial results for the year ended 31 March 2021 on Tuesday 13 July 2021.


Investor meeting

Colin King and Kieron Harbinson will provide a live presentation relating to the Company's Final Results via the Investor Meet Company platform on Tuesday 13 July 2021 at 4:30pm BST.


The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.


Investors can sign up to Investor Meet Company for free and add to meet OMEGA DIAGNOSTICS GROUP PLC via:  


Investors who already follow OMEGA DIAGNOSTICS GROUP PLC on the Investor Meet Company platform will automatically be invited.




Omega Diagnostics Group PLC

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t